Full history for every metric is available with a Kvantra account
Zynerba Pharmaceuticals, Inc. (ZYNE)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -35 | -39 | |||||
| Net profit | $m | -32 | -40 | -31 | -50 | -38 | -35 | -37 |
| EPS reported | $ | -0.82 | -0.78 | |||||
| Operating cashflow per share | $ | -0.54 | -0.54 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.54 | -0.54 | |||||
| Free cash flow | $m | -23 | -32 | |||||
| Net debt | $m | -50 | -36 | |||||
| Book value equity | $m | 46 | 29 | |||||
| Book value per share | $ | 1.08 | 0.58 | |||||
| Number of shares | m | 42.66 | 50.15 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.49 | 2.42 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.98 | -2.20 | |||||
| EV/EBITDA LTM | x | 0.80 | -0.90 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -153.99% | -62.78% | |||||
| FCF Yield | % | -102.52% | -45.41% | |||||
| Quality | ||||||||
| ROE | % | -75.32% | -59.45% | |||||
| ROIC | % | -75.24% | -75.24% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -69.32 | -146.15 | |||||
| Net Debt/EBITDA | x | 1.45 | 1.45 | |||||
| EBIT/Net interest | x | 163.40 | 163.40 | |||||
| Net debt/market cap | % | -222.48% | -51.29% | |||||
| Net debt/Equity | x | -1.09 | -1.24 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zynerba Pharmaceuticals, Inc. (ZYNE)
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free